Greenland Mines (NASDAQ: GRML) has been granted a patent by Innovation, Science and Economic Development Canada for technology exclusively licensed by the company covering Klotho-based gene therapies aimed at treating cognition, memory loss, and neurodegenerative diseases. The patent protects the use of the secreted Klotho (s-KL) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods, and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis.
The company stated that the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China, and Europe. This development is significant as it strengthens Greenland Mines' position in the biotech sector, particularly in the field of gene therapy for neurological conditions that currently have limited treatment options. The patent coverage in Canada, a key market for pharmaceutical innovation, provides a competitive edge and potential revenue streams through licensing or future product sales.
Greenland Mines also announced that process development and manufacturing for its lead candidate, KLTO-101, are scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year. The advancement of these candidates into manufacturing phases indicates progress toward clinical trials and eventual commercialization. KLTO-202 is being developed as a primary indication for ALS, a devastating neurodegenerative disease with high unmet medical need.
The company operates two divisions: mining and biotech. Its mining division focuses on the Skaergaard Project in Greenland and the Sarfartoq rare earths project, while its biotech division includes the Klotho gene therapy platform. This dual focus allows Greenland Mines to diversify its risk and capitalize on opportunities in both the critical minerals and biotechnology sectors. The patent news underscores the company's commitment to advancing its biotech pipeline, which could create significant value for shareholders if the therapies prove successful.
For more details, the full press release is available at https://ibn.fm/x2pHA. Forward-looking statements in the release highlight risks and uncertainties, including those detailed in the company's SEC filings. Investors are advised to review these factors before making investment decisions.
